Di Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Di Sun has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Fanghao Guo
Center for Reproductive Medicine & Fertility Preservation Program, International Peace Maternity and Child Health Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
3 shared publicationsHaixia Ding
Center for Reproductive Medicine & Fertility Preservation Program, International Peace Maternity and Child Health Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
3 shared publications- Wen Li
International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3 shared publications Yanquan Li
Center for Reproductive Medicine & Fertility Preservation Program, International Peace Maternity and Child Health Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
3 shared publications- Meiling Zhang
Center for Reproductive Medicine & Fertility Preservation Program, School of Medicine, International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China
2 shared publications Mengxi Guo
Center for Reproductive Medicine & Fertility Preservation Program, International Peace Maternity and Child Health Hospital School of Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications
Latest Publications
- Open Access
- 17 November 2025
- Published by Wiley in Aging Cell
- Vol. 25 (1) , e70288
Spatial Transcriptomic Characteristics of the Aging Human Ovary
Ovarian aging is a complex process that compromises fertility and elevates the risk of reproductive disorders. To elucidate its spatiotemporal dynamics, we integrated single‐nucleus RNA sequencing and spatial transcriptomics to construct a comprehensive aging atlas of 12 human ovarian tissues spanning ages 12–54 (prepubertal, age 12, n = 1; young, ages 23–29, n = 4; middle‐aged, ages 32–34, n = 2; and older‐aged, ages 42–54, n = 5). Our analysis revealed aging‐related transcriptomic shifts, including impaired mitochondrial oxidative phosphorylation and reproductive structure development in aged human ovaries. We identified a novel endothelial cell (EDC) subtype, CLDN5 + blood EDCs, which exhibited unique functional specialization as semiprofessional antigen‐presenting cells. In contrast to other cell types that lost cell identity during aging, CLDN5 + blood EDCs displayed transcriptomic sensitivity to aging, characterized by enhanced antigen‐presenting capabilities, and heightened inflammatory activity. Spatial mapping further uncovered immunoglobulin‐expressing ( IGHG1 + / IGKC + ) cell accumulation in the ovarian periphery, correlating with advancing age. Critically, aging disrupted global cellular connectivity while amplifying the DLK1:NOTCH3 axis between theca cells and CLDN5 + blood EDCs, which may contribute to the dysregulation of ovarian functions. We also detected the upregulation of DLK1 in granulosa cells from patients with primary ovarian insufficiency. This study significantly enhances our comprehension of the underlying mechanisms of human ovarian aging and concurrently pinpoints potential therapeutic avenues for addressing related disorders.
- 17 November 2025
- Published by Wiley in Aging Cell
- Vol. 25 (1) , e70288
Open AccessSpatial Transcriptomic Characteristics of the Aging Human Ovary
Ovarian aging is a complex process that compromises fertility and elevates the risk of reproductive disorders. To elucidate its spatiotemporal dynamics, we integrated single‐nucleus RNA sequencing and spatial transcriptomics to construct a comprehensive aging atlas of 12 human ovarian tissues spanning ages 12–54 (prepubertal, age 12, n = 1; young, ages 23–29, n = 4; middle‐aged, ages 32–34, n = 2; and older‐aged, ages 42–54, n = 5). Our analysis revealed aging‐related transcriptomic shifts, including impaired mitochondrial oxidative phosphorylation and reproductive structure development in aged human ovaries. We identified a novel endothelial cell (EDC) subtype, CLDN5 + blood EDCs, which exhibited unique functional specialization as semiprofessional antigen‐presenting cells. In contrast to other cell types that lost cell identity during aging, CLDN5 + blood EDCs displayed transcriptomic sensitivity to aging, characterized by enhanced antigen‐presenting capabilities, and heightened inflammatory activity. Spatial mapping further uncovered immunoglobulin‐expressing ( IGHG1 + / IGKC + ) cell accumulation in the ovarian periphery, correlating with advancing age. Critically, aging disrupted global cellular connectivity while amplifying the DLK1:NOTCH3 axis between theca cells and CLDN5 + blood EDCs, which may contribute to the dysregulation of ovarian functions. We also detected the upregulation of DLK1 in granulosa cells from patients with primary ovarian insufficiency. This study significantly enhances our comprehension of the underlying mechanisms of human ovarian aging and concurrently pinpoints potential therapeutic avenues for addressing related disorders.
- Open Access
- 12 July 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3)
Association between Novel per- and poly- fluoroalkyl substances and premature ovarian insufficiency: a case-control study
STUDY QUESTION: Do novel per- and poly- fluoroalkyl substances (novel PFAS) have associations with premature ovarian insufficiency (POI)? SUMMARY ANSWER: Hexafluoropropylene oxide dimer acid (HFPO-DA), perfluorobutanoic acid (PFBA), perfluoropentanoic acid (PFPeA) and perfluoropentanesulfonic acid (PFPeS) are associated with an increased risk of POI, and the effect is worse whith exposure to mixtures. WHAT IS KNOWN ALREADY: As public health concerns following novel PFAS exposure are rising globally, there is a need to understand the exact association between ovel PFAS and various diseases. Epidemiologic studies suggest traditional PFAS exposures adversely affect women’s reproductive health, but the association between exposure to Novel PFAS and POI remains unclear. STUDY DESIGN, SIZE, DURATION: A retrospective research, including 371women, with (case group, n = 151) and without POI (control group, n = 220), were conducted between June 2023 and May 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: Thirteen types of Novel PFAS and basal concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and anti-Müllerian hormone (AMH) in plasma samples were measured in plasma samples collected during the early follicular phase (days 2–5) of a natural menstrual cycle. In addition, characteristics of participants were collected. Both adjusted logistic regression and Bayesian Kernel Machine Regression (BKMR) were used to evaluate associations between Novel PFAS (alone or as a mixture) and POI. Effect modification by age was also investigated. MAIN RESULTS AND THE ROLE OF CHANCE: The concentrations of HFPO-DA, PFBA, PFPeA and PFPeS in the case group were significantly higher than in the reference group. The adjusted logistic regression models demonstrated a positive associations between plasma concentrations of HFPO-DA, PFBA, PFPeA and PFPeS with the risk of POI [ORadj = 2.89 (95%CI: 1.84–4.53), 1.54 (95%CI: 1.17–2.02), 3.12 (95%CI: 2.20–4.43) and 2.07 (95%CI: 1.31–3.27), respectively, per 2.7-fold increase in Novel PFAS concentrations]. High concentrations of Novel PFAS showed a negative correlation with AMH and antral follicle count (AFC), but a positive correlation with FSH. After controlling for other covariates, HFPO-DA, PFBA, PFBS, PFPeA and PFPeS were the major contributors based on the BKMR models. LIMITATIONS, REASONS FOR CAUTION: False positives cannot be ruled out. Therefore, experiments on PFBA, PFPeA, PFPeS and HFPO-DA in vivo also need to be conducted in animal models. WIDER IMPLICATIONS OF THE FINDINGS: Our study is the first to discover the impact of Novel PFAS on the incidence of POI, with aninvestigation of indicators such as AMH, FSH, and AFC. Considering increasingly severe environmental pollution, our research results provides a broader understanding of the impact of environmental endocrine disruptors on ovarian function, and suggests that women of reproductive age should reduce their exposure to Novel PFAS. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Key Research and Development Project of China (2022YFC2703002), National Natural Science Foundation of China (U24A20658, 82371726), Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20212200), Shanghai Hospital Development Center Foundation (SHDC22022303, SHDC22022201) and Key project of Medical and Industrial intersection of Shanghai Jiao Tong University (YG2023ZD27), as well as Reproductive Medicine Research Project of the Chinese Red Cross Foundation (HSZH2024GFYZQ) and Open Fund Project of Shanghai Key Laboratory of Embryogenic Diseases (shelab2023ZD02). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. TRIAL REGISTRATION NUMBER: N/A
- 12 July 2025
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2025 (3)
Open AccessAssociation between Novel per- and poly- fluoroalkyl substances and premature ovarian insufficiency: a case-control study
STUDY QUESTION: Do novel per- and poly- fluoroalkyl substances (novel PFAS) have associations with premature ovarian insufficiency (POI)? SUMMARY ANSWER: Hexafluoropropylene oxide dimer acid (HFPO-DA), perfluorobutanoic acid (PFBA), perfluoropentanoic acid (PFPeA) and perfluoropentanesulfonic acid (PFPeS) are associated with an increased risk of POI, and the effect is worse whith exposure to mixtures. WHAT IS KNOWN ALREADY: As public health concerns following novel PFAS exposure are rising globally, there is a need to understand the exact association between ovel PFAS and various diseases. Epidemiologic studies suggest traditional PFAS exposures adversely affect women’s reproductive health, but the association between exposure to Novel PFAS and POI remains unclear. STUDY DESIGN, SIZE, DURATION: A retrospective research, including 371women, with (case group, n = 151) and without POI (control group, n = 220), were conducted between June 2023 and May 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: Thirteen types of Novel PFAS and basal concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2) and anti-Müllerian hormone (AMH) in plasma samples were measured in plasma samples collected during the early follicular phase (days 2–5) of a natural menstrual cycle. In addition, characteristics of participants were collected. Both adjusted logistic regression and Bayesian Kernel Machine Regression (BKMR) were used to evaluate associations between Novel PFAS (alone or as a mixture) and POI. Effect modification by age was also investigated. MAIN RESULTS AND THE ROLE OF CHANCE: The concentrations of HFPO-DA, PFBA, PFPeA and PFPeS in the case group were significantly higher than in the reference group. The adjusted logistic regression models demonstrated a positive associations between plasma concentrations of HFPO-DA, PFBA, PFPeA and PFPeS with the risk of POI [ORadj = 2.89 (95%CI: 1.84–4.53), 1.54 (95%CI: 1.17–2.02), 3.12 (95%CI: 2.20–4.43) and 2.07 (95%CI: 1.31–3.27), respectively, per 2.7-fold increase in Novel PFAS concentrations]. High concentrations of Novel PFAS showed a negative correlation with AMH and antral follicle count (AFC), but a positive correlation with FSH. After controlling for other covariates, HFPO-DA, PFBA, PFBS, PFPeA and PFPeS were the major contributors based on the BKMR models. LIMITATIONS, REASONS FOR CAUTION: False positives cannot be ruled out. Therefore, experiments on PFBA, PFPeA, PFPeS and HFPO-DA in vivo also need to be conducted in animal models. WIDER IMPLICATIONS OF THE FINDINGS: Our study is the first to discover the impact of Novel PFAS on the incidence of POI, with aninvestigation of indicators such as AMH, FSH, and AFC. Considering increasingly severe environmental pollution, our research results provides a broader understanding of the impact of environmental endocrine disruptors on ovarian function, and suggests that women of reproductive age should reduce their exposure to Novel PFAS. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the National Key Research and Development Project of China (2022YFC2703002), National Natural Science Foundation of China (U24A20658, 82371726), Innovative Research Team of High-Level Local Universities in Shanghai (SHSMU-ZDCX20212200), Shanghai Hospital Development Center Foundation (SHDC22022303, SHDC22022201) and Key project of Medical and Industrial intersection of Shanghai Jiao Tong University (YG2023ZD27), as well as Reproductive Medicine Research Project of the Chinese Red Cross Foundation (HSZH2024GFYZQ) and Open Fund Project of Shanghai Key Laboratory of Embryogenic Diseases (shelab2023ZD02). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. TRIAL REGISTRATION NUMBER: N/A
- Open Access
- 4 April 2025
- Published by Springer Nature in Research Square
Spatiotemporal Dynamics of Human Ovarian Cortex Transcriptome Following Vitrification and Thawing: Insights into the FOS/AP-1 Pathway
Ovary is a vital and dynamic reproductive organ. Ovarian tissue cryopreservation (OTC) plays vital role in female fertility preservation, especially for adolescent female cancer patients. Yet, the sensitive cell populations and cryoinjury molecular mechanisms underlying cryopreservation remain elusive. This study employs single-cell RNA sequencing and spatial transcriptomics to dissect the impacts of temperature stress and cryoprotectant toxicity on the human ovarian cortex. The spatiotemporal molecular characteristics of eight ovarian cell types following vitrification-thawing had been comprehensively characterized. Granulosa, perivascular and stromal cells are identified as most sensitive cell types to OTC procedure. Further analysis using Smart-seq2 on oocytes highlights alterations in“cell cycle” and “DNA methylation” pathways. Notably, the FOS/AP-1 pathway emerges as a crucial response factor to stress and toxicity during cryopreservation. Inhibition of this pathway with T-5224 mitigates vascular damage and reduces apoptosis in vitrification-thawed ovaries. These findings provide insight into the spatiotemporal dynamics during ovarian vitrification and thawing, aiding in prioritizing therapeutic strategies for pre- and post-cryopreservation interventions.
- 4 April 2025
- Published by Springer Nature in Research Square
Open AccessSpatiotemporal Dynamics of Human Ovarian Cortex Transcriptome Following Vitrification and Thawing: Insights into the FOS/AP-1 Pathway
Ovary is a vital and dynamic reproductive organ. Ovarian tissue cryopreservation (OTC) plays vital role in female fertility preservation, especially for adolescent female cancer patients. Yet, the sensitive cell populations and cryoinjury molecular mechanisms underlying cryopreservation remain elusive. This study employs single-cell RNA sequencing and spatial transcriptomics to dissect the impacts of temperature stress and cryoprotectant toxicity on the human ovarian cortex. The spatiotemporal molecular characteristics of eight ovarian cell types following vitrification-thawing had been comprehensively characterized. Granulosa, perivascular and stromal cells are identified as most sensitive cell types to OTC procedure. Further analysis using Smart-seq2 on oocytes highlights alterations in“cell cycle” and “DNA methylation” pathways. Notably, the FOS/AP-1 pathway emerges as a crucial response factor to stress and toxicity during cryopreservation. Inhibition of this pathway with T-5224 mitigates vascular damage and reduces apoptosis in vitrification-thawed ovaries. These findings provide insight into the spatiotemporal dynamics during ovarian vitrification and thawing, aiding in prioritizing therapeutic strategies for pre- and post-cryopreservation interventions.
- 28 February 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (3) , e29468
Assisted reproductive technology treatment failure and the detection of intrauterine HPV through spent embryo transfer media sample
Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital‐based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow‐through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV‐positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV‐positive and 368 HPV‐negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome.
- 28 February 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (3) , e29468
Assisted reproductive technology treatment failure and the detection of intrauterine HPV through spent embryo transfer media sample
Cervical human papillomavirus (HPV) infection is believed to increase the risks of pregnancy failure and abortion, however, whether the uterine cavity HPV infection reduces pregnancy rate or increases miscarriage rate remains unclarified in infertile women undergoing assisted reproductive technology (ART) treatment. Therefore, we aimed to assess ART outcomes in the presence of intrauterine HPV. This was a hospital‐based multicenter (five reproductive medicine centers) matched cohort study. This study involved 4153 infertile women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection treatment in five reproductive medicine centers between October 2018 and 2020. The spent embryo transfer media sample with endometrium tissue were collected and performed with flow‐through hybridization and gene chips to detect HPV DNA. According to basic characteristics, HPV‐positive and negative patients were matched in a ratio of 1:4 by age, body mass index transfer timing, transfer type, and number of embryos transferred. The primary outcome was pregnancy and clinical miscarriage rates in the transfer cycle underwent HPV detection. 92 HPV‐positive and 368 HPV‐negative patients were screened and analyzed statistically. Univariate analysis showed uterine cavity HPV infection resulted in lower rates of ongoing pregnancy (31.5% vs. 44.6%; p = 0.023), implantation (32.3% vs. 43.1%; p = 0.026), biochemical pregnancy (47.8% vs. 62.5%; p = 0.010), and clinical pregnancy (40.2% vs. 54.3%; p = 0.015) compared with HPV negative group. The infertile female with positive HPV also had a slightly higher frequency of biochemical miscarriage (15.9% vs. 13.0%; p = 0.610) and clinical miscarriage (24.3% vs. 15.5%; p = 0.188). These findings suggest that HPV infection in the uterine cavity is a high risk for ART failure. HPV screening is recommended before ART treatment, which may be benefit to improving pregnancy outcome.
- 1 February 2022
- Published by Elsevier in Cancer Letters
- Vol. 526, 311-321
The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation
- 1 February 2022
- Published by Elsevier in Cancer Letters
- Vol. 526, 311-321
The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation